BRUKER CORPORATION (NASDAQ:BRKR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On February16, 2018, Mr.Anthony L. Mattacchione, Chief Financial Officer (CFO) and Senior Vice President of Bruker Corporation (“Bruker,” the “Company,” “we” or “us”), submitted his resignation, effective as of March16, 2018, in order to pursue other interests. Mr.Mattacchione, who has served as the Company’s principal financial officer since 2015 and principal accounting officer since 2016, informed us that he has accepted a position as Chief Financial Officer of Albany Molecular Research,Inc., and will commence service in that position in April2018. Mr.Mattacchione’s resignation is not the result of any dispute or disagreement with the Company or any matter relating to the Company’s accounting practices or financial statements.
Mr.Mattacchione is expected to continue in his role as CFO and principal financial officer until his departure, and he will work during the next few weeks to ensure an orderly transition of his responsibilities. Bruker intends to initiate a search for Mr.Mattacchione’s successor and expects to appoint an interim Chief Financial Officer within weeks. Effective as of February16, 2018, Mr.Mattacchione ceased to serve as the Company’s principal accounting officer and is succeeded in that role by Gerald Herman, Vice President and Corporate Controller, as further described below.
(c) On February16, 2018, the Company appointed Gerald N. Herman, age 60, to serve as the Company’s principal accounting officer. Mr.Herman assumes the role of principal accounting officer from Mr.Mattacchione, effective February16, 2018. Mr.Herman joined the Company in December2016 as Vice President and Corporate Controller and will continue to serve in that capacity following this appointment.
Prior to joining the Company, Mr.Herman served as Corporate Vice President – Clinical Operations of PAREXEL International from 2014 to February2016 and as Corporate Vice President& Controller-Finance of PAREXEL from 2008 to 2013. From 2005 to 2008, Mr.Herman was Vice President-Corporate Controller of Presstek,Inc. Prior to 2005, he served in a variety of financial and accounting roles at various organizations, including as Senior Manager at Arthur Andersen LLP from 1979 to 1987. Mr.Herman is a Certified Public Accountant in the Commonwealth of Massachusetts and holds a M.B.A. from the University of Chicago and a Master of Science in Taxation from Bentley University.
There is no arrangement or understanding between Mr.Herman and any other person to which Mr.Herman was appointed as an officer of the Company. There are no transactions in which Mr.Herman has an interest requiring disclosure under Item 404(a)of Regulation S-K. Mr.Herman receives a base salary comparable to other employees of the Company at his level, and is eligible to participate in the Company’s employee compensation or benefit plans and programs as may be generally made available to other Company employees at his level.
A copy of the Company’s press release is attached as Exhibit99.1 to this Current Report on Form8-K.
Item 9.01 Financial Statements and Exhibits.
|
Number |
|
|
99.1 |
Press release dated February21, 2018. |